<?xml version="1.0" encoding="UTF-8"?>
<p id="Par11">Therapies targeting these pathways may have efficacy later in the response, after traditional antivirals have been found to have reduced effects [
 <xref ref-type="bibr" rid="CR13">13</xref>]. Towards this end, a report found that inhibition of the collagenase MT1-MMP (MMP14) limited tissue damage and improved survival in a mouse model of severe influenza virus infection and in a model of influenza-pneumococcal coinfection [
 <xref ref-type="bibr" rid="CR14">14</xref>]. Targeting the downstream effects of inflammation and immune-associated lung damage may be a viable means of limiting influenza-associated pathology [
 <xref ref-type="bibr" rid="CR15">15</xref>].
</p>
